High titer CAR lentivirus
AMSBIO has introduced a new range of high-titer Chimeric Antigen Receptor (CAR) lentivirus that provide high transduction efficiency with long-term, stable expression in resting and actively dividing cells.
Personalized treatment for cancer reached a new milestone in 2017 with the FDA approval of CAR-T cells for treatment of leukemia and lymphoma. Consequently, there is now rapid growth in research on the therapeutic uses of CAR-T cells.
Increasingly CAR-T cell therapies are being employed as a strategy to redirect a patient’s T-cells to target and destroy specific tumor cells. Researchers have found that viral vectors are the most effective way of transducing CAR into T cells as part of a CAR-T cell manufacturing process.
Due to their ability to stably integrate large DNA inserts, and to efficiently transduce both dividing and non-dividing cells, AMSBIO’s new range of clinical grade CAR lentivirus offers the perfect tool to generate CAR-T cells ex-vivo.
A comprehensive line of CAR lentivirus products is now available from AMSBIO optimized to suit almost any research application. For immunotherapy researchers looking to maximize timelines, AMSBIO can deliver ready-to-transduce CAR lentivirus of up to 10e9 IFU/ml.
For further information please visit https://www.amsbio.com/car-t-cell-research/#1684139755204-0c209941-9ce7 or contact the company on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected]. At the forefront of providing tools for cancer research, AMSBIO has an extensive and growing portfolio of experimental cell lines, recombinant proteins, and screening services to advance the search for new CAR-T cell therapies.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products, and services for R&D in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery.
———————Worldwide HQ AMS Biotechnology (AMSBIO)
184 Milton ParkAbingdon
Oxon OX14 4SE
Email: [email protected]Web www.amsbio.com
North American HQ
AMSBIO LLC1035 Cambridge StreetCambridge MA 02141 USA Email: [email protected]Web www.amsbio.com
Dr Bill Bradbury [email protected]